ClinicaliQ Trial Snapshot
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) — Recruiting • Phase III • Oncology • NCT07227402.
- Treatment being tested: Combination therapy of belzutifan (a HIF-2α inhibitor) and zanzalintinib (a VEGFR/TKI) in patients with recurrent advanced renal cell carcinoma following prior adjuvant therapy, assessing tumour response rates and clinical benefit.
- Patient eligibility overview: Adults with recurrent advanced RCC that has progressed after completion of adjuvant therapy, with measurable disease and adequate organ function; prior systemic therapy experience may apply depending on trial phase.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Eligibility Snapshot
- : The main inclusion criteria include but are not limited to the following: * Has a histologically confirmed diagnosis of unresectable, advanced renal cell cancer (RCC) with clear cell component (with or without sarcomatoid features) i.e., Stage IV renal cell cancer per American Joint Committee on Cancer (AJCC) (8th Edition) * Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) * Has disease recurrence during adjuvant anti-programmed cell death 1/programmed cell death ligand 1 (PD-1/L1) therapy or recurrence ≤24 months following the last dose of adjuvant anti-PD-1/L1 therapy * Has received no other prior systemic therapy for their RCC except for their adjuvant anti-PD-1/L1 therapy
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.